^
Association details:
| Biomarker: | CTNNB1 mutation |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | everolimus (mTOR inhibitor) + letrozole (Aromatase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma
Excerpt:
Patients with endometrioid histology and CTNNB1 mutations responded well to everolimus and letrozole.
DOI:
10.1200/JCO.2014.58.3401
Trial ID:
